- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Lymph vessels.
Displaying page 1 of 2.
| EudraCT Number: 2013-001360-36 | Sponsor Protocol Number: LF-DML-MS | Start Date*: 2013-09-30 |
| Sponsor Name:ULB - Unité de Recherche en Lymphologie - Faculté des Sciences de la motricité | ||
| Full Title: Evaluation of the benefit of lymphofluoroscopy in the validation of the manual drainage techniques on lymphedema | ||
| Medical condition: upper limb lymphedema | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-002501-38 | Sponsor Protocol Number: LY-OCCL-PRESSURE-1 | Start Date*: 2015-07-08 |
| Sponsor Name:ULB - Unité de Recherche en Lymphologie | ||
| Full Title: The occlusion pressure of superficial lymphatics in the upper extremity of healthy volunteers: A Near infrared lymphofluoroscopy approach | ||
| Medical condition: lymphatic pressure in upper limb from healthy volunteers | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-000100-41 | Sponsor Protocol Number: B-AP-ICG-IV | Start Date*: 2013-02-28 |
| Sponsor Name:Jules Bordet Institute | ||
| Full Title: Histological study of the (intravenously injected) Indocyanine Green (ICG) distribution in tumour bearing breasts and in axillary pieces of dissection | ||
| Medical condition: breast cancer | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-000304-96 | Sponsor Protocol Number: NL47648.029.14 | Start Date*: 2015-01-15 | |||||||||||
| Sponsor Name:VU University Medical Center (VUmc) | |||||||||||||
| Full Title: Sentinel lymph node identification in colon cancer using a radioactive and fluorescent tracer | |||||||||||||
| Medical condition: Colon Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-001158-41 | Sponsor Protocol Number: P.64CU.001.01 | Start Date*: 2016-02-19 | |||||||||||
| Sponsor Name:SPARKLE SRL | |||||||||||||
| Full Title: “Technical and diagnostic performances of PET/CT with 64Cu(II)Cl2 in localization of metastases from prostate carcinoma, in patients undergoing restaging for disease progression during ADT” | |||||||||||||
| Medical condition: metastatic prostate carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003825-31 | Sponsor Protocol Number: GDX-44-015 | Start Date*: 2022-02-28 | ||||||||||||||||
| Sponsor Name:Guerbet | ||||||||||||||||||
| Full Title: Gadopiclenol Pharmacokinetics, Safety and Efficacy in Pediatric Patients < 2 Years of Age Undergoing Contrast-enhanced MRI P/0145/2019 | ||||||||||||||||||
| Medical condition: Known or highly suspected abnormalities/ lesion(s) as detected by previous imaging examinations (including the fetal imaging) that need to be investigated by contrast-enhanced MRI of any body regio... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: HU (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-001316-34 | Sponsor Protocol Number: I5B-MC-JGDL | Start Date*: 2016-01-26 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma | |||||||||||||
| Medical condition: soft tissue sarcoma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) ES (Completed) DE (Prematurely Ended) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-001257-31 | Sponsor Protocol Number: TACTIDA | Start Date*: 2021-08-25 | |||||||||||
| Sponsor Name:Department of Pharmaceutical Biosciences, Uppsala University | |||||||||||||
| Full Title: An open, single center two-step trial (A+B), comparing the safety and tolerability of idarubicin 10 mg and 15 mg after separate single hepatic intra-arterial injections of a drug formulation based ... | |||||||||||||
| Medical condition: intermediate stage hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-024483-17 | Sponsor Protocol Number: E7389-G000-309 | Start Date*: 2011-06-30 | |||||||||||
| Sponsor Name:Eisai Ltd | |||||||||||||
| Full Title: A Randomised, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma. | |||||||||||||
| Medical condition: Soft tissue sarcoma (STS) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) CZ (Completed) GB (Completed) AT (Completed) DK (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002677-22 | Sponsor Protocol Number: TVECUSDoppler | Start Date*: 2020-02-05 |
| Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||
| Full Title: Doppler sonography of skin and nodal metastases as a predictor of clinical response to Talimogene Laherparepvec (T-VEC) in melanoma patients (T-VEC – US Doppler) | ||
| Medical condition: Melanoma stage IIIB-IVM1a | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-001761-11 | Sponsor Protocol Number: 300488 | Start Date*: 2015-08-31 | ||||||||||||||||
| Sponsor Name:The Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital | ||||||||||||||||||
| Full Title: Lymphatic dysfunction as a cause of calcium channel blocker oedema in post-menopausal women | ||||||||||||||||||
| Medical condition: Calcium channel antagonist induced peripheral edema in post-menopausal women. We hypothesize that this condition is partly due to impaired lymphatic function in these patients. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-000783-16 | Sponsor Protocol Number: ML21531 | Start Date*: 2008-06-18 | ||||||||||||||||
| Sponsor Name:ROCHE SAS | ||||||||||||||||||
| Full Title: Multicenter, phase II trial assessing the efficacy and safety of bevacizumab (Avastin®) combined to trastuzumab (Herceptin®) based chemotherapy in patients with primary inflammatory HER2+ breast ca... | ||||||||||||||||||
| Medical condition: Primary inflammatory HER2+ breast cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: FR (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2007-002105-44 | Sponsor Protocol Number: ML20982 | Start Date*: 2008-07-02 | ||||||||||||||||
| Sponsor Name:Military Medical Academy Hospital for Active Treatment, Sofia | ||||||||||||||||||
| Full Title: Open – label, non randomized clinical study of Neoadjuvant chemotherapy with FOLFIRI and Avastin in patients with non-resectable liver metastases of colorectal cancer | ||||||||||||||||||
| Medical condition: Metastatic (liver metastases) colorectal cancer, with no prior chemotherapy. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BG (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-002857-12 | Sponsor Protocol Number: GO40241 | Start Date*: 2018-04-26 | |||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
| Full Title: A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY I... | |||||||||||||
| Medical condition: Early Stage Resectable Non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) SI (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) HU (Completed) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-001361-28 | Sponsor Protocol Number: GO29365 | Start Date*: 2015-10-07 | |||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||||||||||||
| Full Title: A Phase Ib/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin in combination with rituximab (R) or obinutuzumab (G) plus bendamustine (B) in relapsed or ref... | |||||||||||||||||||||||
| Medical condition: Follicular Lymphoma and Diffuse Large B-Cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Completed) FR (Ongoing) IT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2012-002935-27 | Sponsor Protocol Number: 41208 | Start Date*: 2012-12-13 | |||||||||||||||||||||||||||||||
| Sponsor Name:Maastricht University Medical Center | |||||||||||||||||||||||||||||||||
| Full Title: Diagnostic value of novel MR imaging techniques for the primary staging and restaging of rectal cancer | |||||||||||||||||||||||||||||||||
| Medical condition: rectal cancer | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-004377-84 | Sponsor Protocol Number: GO27834 | Start Date*: 2013-04-11 | ||||||||||||||||||||||||||
| Sponsor Name:Genentech, Inc. | ||||||||||||||||||||||||||||
| Full Title: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of pinatuzumab vedotin (DCDT2980S) in combination with rituximab or polatuzumab vedotin (DCDS4501A) in combi... | ||||||||||||||||||||||||||||
| Medical condition: Follicular Non-Hodgkin’s Lymphoma (FL); Diffuse Large B-Cell Lymphoma (DLBCL) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) IT (Completed) NL (Completed) FR (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2016-004718-90 | Sponsor Protocol Number: UTX-TGR-205 | Start Date*: 2017-10-10 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:TG Therapeutics | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Ho... | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Non-Hodgkin lymphoma | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) PL (Prematurely Ended) SK (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-005076-26 | Sponsor Protocol Number: SGNTV-001 | Start Date*: 2019-04-16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Seagen, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Locally Advanced or Metastatic Disease in Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-006174-47 | Sponsor Protocol Number: FC-004 | Start Date*: 2012-06-08 | |||||||||||
| Sponsor Name:ProFibrix BV | |||||||||||||
| Full Title: A Phase 3, Randomized, Single-Blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical Haemostasis | |||||||||||||
| Medical condition: Intraoperative Surgical Hemostasis (Spinal Surgery, Vascular Surgery, Hepatic resection, Soft tissue dissection) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) NL (Completed) GB (Completed) | |||||||||||||
| Trial results: Removed from public view | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
